From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | Local Control | Distant progression free survival | Overall Survival | Toxicity |
---|---|---|---|---|
Weickhardt et al. (2012) [29] | N.S. | 6.2 months | N.S. | 2 ≥ G3 |
Iyengar et al. (2014) [23] | N.S. | 14.7 months | 20.4 months | 2 > G3 |
Borghetti et al. (2019) [25] | N.S. | N.S. | 23 months | 0 > G3 |
Qiu et al. (2017) [24] | 81.4% | 7 months | 35 months | 2 > G3 |
Rossi et al. (2019) [26] | N.S. | 13.8 months | 35 months | N.S. |
Weiss et al. (2019) [30] | N.S. | 6 months | 29 months | N.S. |
Chan OSH et al. (2018) [31] | N.S. | 15 months | N.S. | 0 > G3 |
Xu et al. (2018) [27] | N.S. | 20.6 months | 40.9 months | 14% > G3 |